Could a hormone patch ease suicidal thoughts during periods?
NCT ID NCT06191289
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a transdermal estrogen patch, applied for two weeks around the menstrual period, could reduce suicidal thoughts in women who had recently experienced them. Eleven women participated, and the study compared the estrogen patch to a placebo patch. The goal was to see if boosting estrogen levels could help stabilize mood and reduce suicidal ideation during a vulnerable time of the month.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
transdermal estradiol (estrogen patch)
What this could lead to
If it works, this could point toward a short-term hormone treatment to ease suicidal thoughts during the menstrual period.
What could go wrong
This was a very small, early-phase study that was terminated early, so results are limited. The treatment is only for a specific time window and may not help everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUICIDE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Illinois Neuropsychiatric Institute
Chicago, Illinois, 60612, United States